{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T15:02:50Z","timestamp":1775746970828,"version":"3.50.1"},"reference-count":16,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2025,1,20]],"date-time":"2025-01-20T00:00:00Z","timestamp":1737331200000},"content-version":"vor","delay-in-days":19,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["alz-journals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["A&amp;amp;D Transl Res &amp;amp; Clin Interv"],"published-print":{"date-parts":[[2025,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:label\/>\n                    <jats:p>Despite some skepticism regarding the amyloid hypothesis, there is growing evidence that clearing amyloid by targeting specific species of amyloid (plaque, oligomers, fibrils, and protofibrils) for removal has therapeutic benefits. Specifically, there is growing evidence that, in mild cognitive impairment and mild dementia due to Alzheimer's disease (AD), robust and aggressive removal of amyloid can slow cognitive decline as measured by global instruments, composite measures, and cognitive testing. Furthermore, clinical efficacy signals coupled with clear biomarker changes provide the first evidence of disease modification. This effect seems to be in addition to symptomatic treatments and opens speculation that the effect of anti\u2010amyloid monoclonal antibodies might be clinically meaningful through symptomatic amelioration that is a result of disease modification.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Highlights<\/jats:title>\n                    <jats:p>\n                      <jats:list list-type=\"bullet\">\n                        <jats:list-item>\n                          <jats:p>Clearance of brain amyloid plaques may lead to a clinical benefit in patients with early AD.<\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>Aggregated A\u03b2 may play a role in both disease expression and progression.<\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>Anti\u2010amyloid monoclonal antibodies might be clinically meaningful through symptomatic amelioration resulting from disease modification.<\/jats:p>\n                        <\/jats:list-item>\n                      <\/jats:list>\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/trc2.70035","type":"journal-article","created":{"date-parts":[[2025,1,20]],"date-time":"2025-01-20T23:37:11Z","timestamp":1737416231000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Perspective: Minimally clinically important \u201csymptomatic\u201d benefit associated with disease modification resulting from anti\u2010amyloid immunotherapy"],"prefix":"10.1002","volume":"11","author":[{"given":"John","family":"Alam","sequence":"first","affiliation":[{"name":"CervoMed, Inc.  Boston Massachusetts USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8139-3309","authenticated-orcid":false,"given":"Marwan N.","family":"Sabbagh","sequence":"additional","affiliation":[{"name":"Department of Neurology Barrow Neurological Institute St. Joseph's Hospital and Medical Center  Phoenix Arizona USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2025,1,20]]},"reference":[{"issue":"17","key":"e_1_2_8_2_1","first-page":"1631","article-title":"Lecanemab in early Alzheimer's disease. Reply","volume":"388","author":"Dyck CH","year":"2023","journal-title":"N Engl J Med"},{"issue":"6","key":"e_1_2_8_3_1","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1001\/jama.2023.13239","article-title":"Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER\u2010ALZ 2 randomized clinical trial","volume":"330","author":"Sims JR","year":"2023","journal-title":"JAMA"},{"issue":"3","key":"e_1_2_8_4_1","article-title":"Meaningful benefit and minimal clinically important difference (MCID) in Alzheimer's disease: open peer commentary","volume":"9","author":"Cummings J","year":"2023","journal-title":"Alzheimers Dement"},{"issue":"1","key":"e_1_2_8_5_1","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1370\/afm.3050","article-title":"Clinically important benefits and harms of monoclonal antibodies targeting amyloid for the treatment of Alzheimer disease: a systematic review and meta\u2010analysis","volume":"22","author":"Ebell MH","year":"2024","journal-title":"Ann Fam Med"},{"issue":"6","key":"e_1_2_8_6_1","doi-asserted-by":"crossref","first-page":"595","DOI":"10.15252\/emmm.201606210","article-title":"The amyloid hypothesis of Alzheimer's disease at 25 years","volume":"8","author":"Selkoe DJ","year":"2016","journal-title":"EMBO Mol Med"},{"issue":"3","key":"e_1_2_8_7_1","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.nbd.2009.08.007","article-title":"An amyloid\u2010beta protofibril\u2010selective antibody prevents amyloid formation in a mouse model of Alzheimer's disease","volume":"36","author":"Lord A","year":"2009","journal-title":"Neurobiol Dis"},{"issue":"1","key":"e_1_2_8_8_1","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1124\/jpet.117.240614","article-title":"Glutaminyl cyclase inhibitor PQ912 improves cognition in mouse models of Alzheimer's disease\u2010studies on relation to effective target occupancy","volume":"362","author":"Hoffmann T","year":"2017","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_2_8_9_1","unstructured":"vanDyckCH SperlingRA DhaddaS et\u00a0al.Is there Evidence for a Continued Benefit for Long\u2010Term Lecanemab Treatment? A Benefit\/Risk Update from Long\u2010Term Efficacy Safety and Biomarker Data.Perspectives Session at Alzheimer's Association International Conference (AAIC). 28 July \u2010 1 August 2024.Philadelphia PA USA.EISAI;2024. Accessed November 2 2024.https:\/\/www.eisai.com\/ir\/library\/presentations\/pdf\/4523_240731_1.pdf"},{"key":"e_1_2_8_10_1","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/j.brainres.2016.03.029","article-title":"The UPR and synaptic dysfunction in neurodegeneration","volume":"1648","author":"Freeman OJ","year":"2016","journal-title":"Brain Res"},{"issue":"12","key":"e_1_2_8_11_1","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1056\/NEJMoa2305032","article-title":"Trial of solanezumab in preclinical Alzheimer's disease","volume":"389","author":"Sperling RA","year":"2023","journal-title":"N Engl J Med"},{"issue":"2","key":"e_1_2_8_12_1","doi-asserted-by":"crossref","first-page":"197","DOI":"10.14283\/jpad.2022.30","article-title":"Two randomized phase 3 studies of aducanumab in early Alzheimer's disease","volume":"9","author":"Budd Haeberlein S","year":"2022","journal-title":"J Prev Alzheimers Dis"},{"issue":"20","key":"e_1_2_8_13_1","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.1056\/NEJMoa2304430","article-title":"Two phase 3 trials of gantenerumab in early Alzheimer's disease","volume":"389","author":"Bateman RJ","year":"2023","journal-title":"N Engl J Med"},{"issue":"1","key":"e_1_2_8_14_1","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s13195-024-01412-z","article-title":"The search for clarity regarding \u201cclinically meaningful outcomes\u201d in Alzheimer disease clinical trials: CLARITY\u2010AD and beyond","volume":"16","author":"Tarawneh R","year":"2024","journal-title":"Alzheimers Res Ther"},{"issue":"6","key":"e_1_2_8_15_1","doi-asserted-by":"crossref","first-page":"2730","DOI":"10.1002\/alz.12959","article-title":"Expectations and clinical meaningfulness of randomized controlled trials","volume":"19","author":"Petersen RC","year":"2023","journal-title":"Alzheimers Dement"},{"issue":"1","key":"e_1_2_8_16_1","doi-asserted-by":"crossref","first-page":"5308","DOI":"10.1038\/s41467-022-32944-3","article-title":"Preclinical and randomized clinical evaluation of the p38alpha kinase inhibitor neflamapimod for basal forebrain cholinergic degeneration","volume":"13","author":"Jiang Y","year":"2022","journal-title":"Nat Commun"},{"issue":"1","key":"e_1_2_8_17_1","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1186\/s12974-023-02853-3","article-title":"Tau and neuroinflammation in Alzheimer's disease: interplay mechanisms and clinical translation","volume":"20","author":"Chen Y","year":"2023","journal-title":"J Neuroinflammation"}],"container-title":["Alzheimer's &amp; Dementia: Translational Research &amp; Clinical Interventions"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/alz-journals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/trc2.70035","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T15:17:27Z","timestamp":1761491847000},"score":1,"resource":{"primary":{"URL":"https:\/\/alz-journals.onlinelibrary.wiley.com\/doi\/10.1002\/trc2.70035"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":16,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["10.1002\/trc2.70035"],"URL":"https:\/\/doi.org\/10.1002\/trc2.70035","archive":["Portico"],"relation":{},"ISSN":["2352-8737","2352-8737"],"issn-type":[{"value":"2352-8737","type":"print"},{"value":"2352-8737","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"2024-09-04","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-11-20","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-01-20","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70035"}}